Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frunexian for Thromboprophylaxis in COVID-19 ICU Patients
NCT05040776Phase 2Withdrawn
- Sponsor
- eXIthera
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of frunexian in coronavirus disease 2019 (COVID-19), sponsored by eXIthera. Planned start Oct 2023; status: withdrawn.
02
Drugs
frunexian
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05040776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040776.